D-0734-2021 Class II Terminated

Recalled by Teva Pharmaceuticals USA — Parsippany, NJ

FDA drug recall D-0734-2021 was initiated by Teva Pharmaceuticals USA on Jul 29, 2021 and is designated Class II. Reason for recall: Lack of Assurance of Sterility The recall status is terminated (terminated Jun 4, 2024). Affected quantity: 2,091 vials.

Recall details

Product Type
Drugs
Report Date
Aug 25, 2021
Initiation Date
Jul 29, 2021
Termination Date
Jun 4, 2024
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
2,091 vials

Product description

Idarubicin Hydrochloride Injection 20 mg/20 mL, 20 mL single-dose vial, Rx only, Teva Pharmaceuticals USA, Inc. North Wales, PA 19454, NDC 0703-4156-11

Reason for recall

Lack of Assurance of Sterility

Distribution pattern

Product was distributed Nationwide, including Puerto Rico.

Code information

Lot #: 31328668B, exp. date 04/2023

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0734-2021
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0734-2021. Report a data issue: hello@regdatalab.com.